首頁 > 市場調查報告書 > 醫療設備

心血管設備循環系統

市場調查報告書

商品編碼

1297802

全球心房顫動市場 - 2023-2030年

Global Atrial Fibrillation Market - 2023-2030

出版日期: 2023年06月15日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

全球心房顫動市場在2022年達到193億美元，預計到2030年將見證有利可圖的成長，達到428億美元。在2023-2030年的預測期內，全球心房顫動市場預計將呈現10.7%的複合成長率。

心房顫動（A-fib）是一種心律失常（一種不規則的、通常非常快的心律），可導致心臟內的血栓。中風、心力衰竭和其他與心臟有關的問題都會因心房顫動而增加。

在心房顫動期間，心臟的上腔（心房）混亂而不規則地跳動，與下腔（心室）的節奏不一致。許多患有心房顫動的人沒有任何症狀。反之，心房顫動可引起快速、敲擊式的心跳（心悸）、呼吸短促或虛弱。

市場動態

肥胖和心臟疾病負擔的增加推動了市場的成長

心房顫動市場受到全球肥胖和心臟疾病發病率上升的推動。此外，心臟病是全世界死亡的主要原因之一，由於生活方式的改變，患心臟病的人數正在激增。肥胖與患心血管疾病（CVD）的風險增加有關，特別是心力衰竭（HF）和冠心病（CHD）。

肥胖增加心血管疾病風險的機制涉及身體成分的變化，可以影響血液動力學和改變心臟結構。脂肪組織產生的促炎症細胞因子可以誘發心臟功能障礙並促進動脈粥樣硬化斑塊的形成。

缺乏有效治療心房顫動的策略

由於缺乏對心房顫動發病機制的透徹了解，以及抗心律失常藥物治療的低效率和不良反應，對治療心房顫動構成了重大障礙。

心房顫動患者的數量不斷擴大，對抗凝、抗心律失常藥物和控制心率藥物等治療方案的需求不斷增加，使正常的衛生保健系統負擔加重。此外，對心房顫動和潛在的治療技術缺乏認知和了解，正在減緩對心房顫動治療設備和程序的接受。

COVID-19的影響分析

COVID-19對心房顫動的影響是巨大的；根據一項綜合研究，心房顫動的發生率在COVID-19患者中佔8%，與年齡較大、男性和高血壓有關。與沒有心房顫動的患者相比，心房顫動患者的全因死亡風險更大。在新診斷的心房顫動患者中也出現了類似的結果。

這些發現突出了心房顫動對COVID-19患者的負面影響，並支持有必要為並發心房顫動的COVID-19患者的預防、診斷和治療制定獨特和有針對性的措施。需要更多的研究來確定監測這些人的最佳方法，特別是抗血栓治療。

Market Overview

The Global Atrial Fibrillation Market reached US$ 19.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 42.8 billion by 2030. The Global Atrial Fibrillation Market is expected to exhibit a CAGR of 10.7% during the forecast period 2023-2030.

Atrial fibrillation (A-fib) is an arrhythmia (an irregular and typically very fast heart rhythm) that can result in blood clots in the heart. Stroke, heart failure, and other heart-related problems are all increased by atrial fibrillation.

During atrial fibrillation, the heart's top chambers (the atria) beat chaotically and irregularly, out of rhythm with the bottom chambers (the ventricles). Many persons with atrial fibrillation have no symptoms. Atrial fibrillation, conversely, can induce a rapid, hammering heartbeat (palpitations), shortness of breath, or weakness.

Market Dynamics

The Rising Burden of Obesity and Heart Diseases Drives the Market Growth

The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality around the world, and due to the changing lifestyle, the number of people suffering from heart diseases is proliferating. Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD).

The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue can induce cardiac dysfunction and promote the formation of atherosclerotic plaques.

Lack of Strategies to Effectively Treat Atrial Fibrillation

The absence of a thorough knowledge of the pathogenesis of atrial fibrillation, as well as the inefficiency and adverse effects associated with antiarrhythmic medication therapy, pose significant obstacles in treating atrial fibrillation.

The expanding number of patients with atrial fibrillation and the growing need to adapt treatment options such as anticoagulation, antiarrhythmic medicines, and rate control medications is increasing the normal health care system load. Furthermore, a lack of awareness and understanding concerning atrial fibrillation and potential therapeutic techniques is slowing the uptake of atrial fibrillation therapy devices and procedures.

COVID-19 Impact Analysis

The influence of COVID-19 on atrial fibrillation was enormous; according to a comprehensive study, the incidence of atrial fibrillation was 8% of COVID-19 patients and was related to older age, male sex, and hypertension. Patients with Atrial Fibrillation had a greater risk of all-cause death than those who did not have atrial fibrillation. Similar results were seen in patients with newly diagnosed atrial fibrillation.

The findings highlight the negative effect of atrial fibrillation in COVID-19 patients and support the necessity for developing unique and targeted measures for the prevention, diagnosis, and therapy of COVID-19 patients with concurrent AF. More research is needed to determine the best ways to monitor these individuals, particularly antithrombotic treatments.

Segment Analysis

The Global Atrial Fibrillation Market is segmented based on treatment type and end user.

The Ambulatory Surgical Center Segment is Expected to Grow During the Forecast Period

The ambulatory surgical center segment is expected to witness good growth of around 33.3% due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure are expected to propel the market.

However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, encourage patients to opt for minimally invasive surgeries, which is expected to boost market growth.

Geographical Analysis

North America is the dominating region during the forecast period.

The North American region is expected to dominate the atrial fibrillation market and account for around 41.5% in the forecast period. This is majorly attributed to the rising patient pool in the region and the presence of key players.

The North American region is predicted to lead the worldwide atrial fibrillation market due to the growing acceptance of technologically sophisticated devices and a significant increase in cardiac problems among the aging and general population.

Furthermore, a well-established healthcare infrastructure is projected to support the market's long-term expansion in North America. During the projection period, the North American atrial fibrillation market benefit from patient's high disposable income and growing fibrillation prevalence.

Competitive Landscape

The major global players include: AtriCure, Biosense Webster, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, Cardio Focus, Endoscopic Technologies, Sanofi Aventis, Abbott, Johnson and Johnson.

Why Purchase the Report?

To visualize the Global Atrial Fibrillation Market segmentation based on the treatment type, end user and region, and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous atrial fibrillation market level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Atrial Fibrillation Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1 Snippet by Treatment Type
3.2 Snippet by End User
3.3 Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1 Increase in Developed Treatments
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Strategies to Effectively Treat Atrial Fibrillation
- 4.1.3. Opportunity
  - 4.1.3.1. Development of Technology
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Treatment Type

Non-Pharmacological Treatment

Maze Surgery

Catheter Ablation

Radiofrequency Based
HIFU Based
Cryoablation Based
Others

Electric Cardioversion

Pharmacological Treatment

Anti-arrhythmic Drugs

Anti-coagulant Drugs

8. By Region

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.5.1. The U.S.
  - 8.2.5.2. Canada
  - 8.2.5.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.5.1. Germany
  - 8.3.5.2. The UK
  - 8.3.5.3. France
  - 8.3.5.4. Italy
  - 8.3.5.5. Spain
  - 8.3.5.6. Rest of Europe
8.4. South America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.5.1. Brazil
  - 8.4.5.2. Argentina
  - 8.4.5.3. Rest of South America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.5.1. China
  - 8.5.5.2. India
  - 8.5.5.3. Japan
  - 8.5.5.4. Australia
  - 8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country